Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in Egypt

This clinical trial is being conducted to see if a medicine called ursodeoxycholic acid (UDCA) can help reduce inflammation and disease activity in people with rheumatoid arthritis. Rheumatoid arthritis is a condition where the body's immune system attacks its own joints, leading to pain and swelling. The study focuses on patients in Egypt who are already receiving standard treatments for rheumatoid arthritis but still experience varying levels of disease activity. By adding UDCA to their treatment regimen, researchers hope to find an effective way to improve the lives of these patients by potentially reducing joint inflammation and improving overall disease management. In this study, 60 people with rheumatoid arthritis will participate. They will be divided into two groups; one group will receive their usual arthritis medications along with a placebo, while the other group will receive their usual medications plus UDCA at a dose of 500 mg per day. This treatment will continue for 24 weeks. Researchers will conduct medical exams and laboratory tests at the start, then again at 12 weeks and 24 weeks, to assess how well UDCA is working. They will be looking at how UDCA affects inflammation and disease activity in the participants. The study is designed to track the safety and potential benefits of adding UDCA to standard rheumatoid arthritis treatments.